公开(公告)号：US20180369378A1

公开(公告)日：2018-12-27

申请号：US16032604

申请日：2018-07-11

申请人： Institut National de la Sante et de la Recherche Medicale (INSERM) ,  Centre Hospitalier Universitaire de Rouen ,  Universite de Rouen ,  TARGEDYS

发明人： Serguei Fetissov ,  Emmanuelle De ,  Naouel Tennoune ,  Jonathan Breton ,  Philippe Chan-Tchi-Song ,  Pierre Dechelotte ,  Romain Legrand ,  Gregory Lambert

IPC分类号： A61K39/40 ,  A61P1/14

CPC分类号： A61K39/40 ,  A61K2039/545 ,  A61K2039/55516 ,  A61P1/14 ,  C07K14/245 ,  C07K16/1232 ,  C07K16/26 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/76

摘要： The present invention relates to CIpB expressing bacteria and their impact on obesity. The present invention relates to bacterial CIpB protein and CIpB expressing bacteria and their impact on eating disorders. The invention further relates to compositions comprising antibiotic directed against at least one CIpB expressing bacterium as well as probiotics not expressing CIpB protein and their use in the treatment or prevention of eating disorders. The invention also relates to diagnostic tools for determining whether a subject is likely to respond to a method of treating eating disorders and to methods of immunization against eating disorders.

公开(公告)号：US20210008125A1

公开(公告)日：2021-01-14

申请号：US16902732

申请日：2020-06-16

申请人： Institut National de la Sante et de la Recherche Medicale (INSERM) ,  Centre Hospitalier Universitaire de Rouen ,  Universite de Rouen ,  TARGEDYS

发明人： Serguei Fetissov ,  Emmanuelle De ,  Naouel Tennoune ,  Jonathan Breton ,  Philippe Chan-Tchi-Song ,  Pierre Dechelotte ,  Romain Legrand ,  Gregory Lambert

IPC分类号： A61K35/741 ,  A61P3/04 ,  A61P3/10 ,  A61P3/06 ,  A23L33/135

摘要： The present invention relates to method of preventing, treating or attenuating obesity-related manifestations in a human or non-human mammal subject in need thereof, said method comprising orally administering to the subject a composition comprising an effective amount Hafnia alvei probiotics; wherein said obesity-related parameters are selected from the group of hyperphagia, increased fat mass on lean mass ratio, increased waist circumference, postprandial hyperglycemia, fasting hyperglycemia and hypercholesterolemia.

公开(公告)号：US10729770B2

公开(公告)日：2020-08-04

申请号：US16032604

申请日：2018-07-11

申请人： Institut National de la Sante et de la Recherche Medicale (INSERM) ,  Centre Hospitalier Universitaire de Rouen ,  Universite de Rouen ,  TARGEDYS

发明人： Serguei Fetissov ,  Emmanuelle De ,  Naouel Tennoune ,  Jonathan Breton ,  Philippe Chan-Tchi-Song ,  Pierre Dechelotte ,  Romain Legrand ,  Gregory Lambert

IPC分类号： A61K39/40 ,  A61P1/14 ,  C07K14/245 ,  C07K16/12 ,  C07K16/26 ,  A61K39/00

摘要： The present invention relates to ClpB expressing bacteria and their impact on obesity. The present invention relates to bacterial ClpB protein and ClpB expressing bacteria and their impact on eating disorders. The invention further relates to compositions comprising antibiotic directed against at least one ClpB expressing bacterium as well as probiotics not expressing ClpB protein and their use in the treatment or prevention of eating disorders. The invention also relates to diagnostic tools for determining whether a subject is likely to respond to a method of treating eating disorders and to methods of immunization against eating disorders.

公开(公告)号：US20160313348A1

公开(公告)日：2016-10-27

申请号：US15101452

申请日：2014-12-04

申请人： Institut National de la Sante et de la Recherche Medicale (INSERM) ,  Centre Hospitalier Universitaire de Rouen ,  Universite de Rouen

发明人： Serguei Fetissov ,  Emmanuelle De ,  Naouel Tennoune ,  Jonathan Breton ,  Philippe Chan-Tchi-Song ,  Pierre Dechelotte ,  Romain Legrand

IPC分类号： G01N33/68 ,  A61K39/108 ,  C12Q1/68 ,  A61K35/741

CPC分类号： G01N33/6893 ,  A61K31/00 ,  A61K31/11 ,  A61K35/741 ,  A61K39/0258 ,  A61K2039/58 ,  C12Q1/6883 ,  C12Q2600/158 ,  G01N2800/02 ,  G01N2800/52 ,  Y02A50/474

摘要： The present invention relates to bacterial Clp B protein and Clp B expressing bacteria and their impact on eating disorders. The invention further relates to compositions comprising antibiotic directed against at least one Clp B expressing bacterium as well as probiotics not expressing Clp B protein and their use in the treatment or prevention of eating disorders. The invention also relates to diagnostic tools for determining whether a subject is likely to respond to a method of treating eating disorders and to methods of immunization against eating disorders.

摘要翻译： 本发明涉及细菌Clp B蛋白和Clp B表达细菌及其对进食障碍的影响。 本发明还涉及包含针对至少一种ClP B表达细菌的抗生素以及不表达Clp B蛋白的益生菌及其在治疗或预防进食障碍中的用途的组合物。 本发明还涉及用于确定受试者是否可能对治疗进食障碍的方法作出反应的诊断工具以及针对进食障碍的免疫方法。